Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).

  2. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

  3. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    [A258948] A pooled analysis of five prospective clinical trials found that the use of omidubicel led to stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up … In this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching.

  4. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. … It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.

  5. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.

  6. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and … It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

  7. Drug

    Pyrazinamide

    go.drugbank.com/drugs/DB00339
    ApprovedInvestigational

    A pyrazine that is used therapeutically as an antitubercular agent.

  8. Target

    Transient receptor potential cation channel subfamily A member 1

    go.drugbank.com/bio_entities/BE0001122
    TargetHumans

    Also acts as an ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312).

    Polypeptides: Transient receptor potential cation channel subfamily A member 1Synonyms: Wasabi receptor
  9. Target

    Transient receptor potential cation channel subfamily M member 8

    go.drugbank.com/bio_entities/BE0001186
    TargetHumans

    Non-selective ion channel permeable to monovalent and divalent cations, including Na(+), K(+), and Ca(2+), with higher permeability for Ca(2+). Activated by multiple factors, such as temperature, voltage, pressure, and changes in osmolal...

    Polypeptides: Transient receptor potential cation channel subfamily M member 8Synonyms: Transient receptor potential p8, Long transient receptor potential channel 6
  10. Target

    Low affinity immunoglobulin gamma Fc region receptor III-A

    go.drugbank.com/bio_entities/BE0002097
    TargetHumans

    Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). … The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-ASynonyms: IgG Fc receptor III-2, IgG Fc receptor III-A